J. Hilfrich

11.6k total citations · 1 hit paper
96 papers, 6.5k citations indexed

About

J. Hilfrich is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Hilfrich has authored 96 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 54 papers in Cancer Research and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Hilfrich's work include Breast Cancer Treatment Studies (48 papers), Cancer Treatment and Pharmacology (33 papers) and HER2/EGFR in Cancer Research (25 papers). J. Hilfrich is often cited by papers focused on Breast Cancer Treatment Studies (48 papers), Cancer Treatment and Pharmacology (33 papers) and HER2/EGFR in Cancer Research (25 papers). J. Hilfrich collaborates with scholars based in Germany, United States and Switzerland. J. Hilfrich's co-authors include Gϋnter von Minckwitz, Holger Eidtmann, Christian Jackisch, Jens‐Uwe Blohmer, Sibylle Loibl, Jens Huober, Serban Dan Costa, Manfred Kaufmann, Michael Untch and Bernd Gerber and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

J. Hilfrich

94 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by J. Hilfrich

Since Specialization

Citations

This map shows the geographic impact of J. Hilfrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Hilfrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Hilfrich more than expected).

Fields of papers citing papers by J. Hilfrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Hilfrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Hilfrich. The network helps show where J. Hilfrich may publish in the future.

Co-authorship network of co-authors of J. Hilfrich

This figure shows the co-authorship network connecting the top 25 collaborators of J. Hilfrich. A scholar is included among the top collaborators of J. Hilfrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Hilfrich. J. Hilfrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial 2017 ·Clinical Cancer Research ·Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, Valentina Nekljudova, Karsten Weber, Jens Huober, Tanja Fehm, Iris Schrader, J. Hilfrich, Frank Holms, Hans Tesch, Christian Schem, Gϋnter von Minckwitz, Michael Untch, Klaus Pantel	82
2	Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) 2017 ·European Journal of Cancer ·Sherko Kümmel, Stefan Paepke, Jens Huober, Christian Schem, Michael Untch, Jens‐Uwe Blohmer, W. Eiermann, Bernd Gerber, Claus Hanusch, J. Hilfrich, Christian Jackisch, Andreas Schneeweiß, Carsten Denkert, Knut Engels, Peter Klare, Peter A. Fasching, Gϋnter von Minckwitz, Nicole Burchardi, Sibylle Loibl	17
3	Response-Guided Neoadjuvant Chemotherapy for Breast Cancer 2013 ·Journal of Clinical Oncology ·Gϋnter von Minckwitz, Jens‐Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, W. Eiermann, Bernd Gerber, Claus Hanusch, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Sherko Kümmel, Stefan Paepke, Andreas Schneeweiß, Michael Untch, Dirk M. Zahm, Keyur Mehta, Sibylle Loibl	265
4	Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial 2013 ·Annals of Oncology ·Carsten Denkert, Sibylle Loibl, Berit Müller, Holger Eidtmann, Wolfgang Schmitt, W. Eiermann, B. Gerber, Hans Tesch, J. Hilfrich, Jens Huober, Tanja Fehm, Jana Barinoff, Christian Jackisch, Judith Prinzler, Thomas Rüdiger, E Erbstösser, Jens‐Uwe Blohmer, Jan Budczies, K. Mehta, Gϋnter von Minckwitz	172
5	Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro) 2013 ·Annals of Oncology ·Gϋnter von Minckwitz, Mahdi Rezai, Peter A. Fasching, Jens Huober, Hans Tesch, Ingo Bauerfeind, J. Hilfrich, Holger Eidtmann, B. Gerber, Claus Hanusch, Jens‐Uwe Blohmer, Serban Dan Costa, Christian Jackisch, Stefan Paepke, Andreas Schneeweiß, Sherko Kümmel, Carsten Denkert, K. Mehta, Sibylle Loibl, Michael Untch	51
6	RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy 2012 ·Annals of Oncology ·Carsten Denkert, Sibylle Loibl, Ralf Kronenwett, Jan Budczies, Christian von Törne, Valentina Nekljudova, Silvia Darb‐Esfahani, Christine Solbach, Bruno V. Sinn, Christoph Petry, Berit Müller, J. Hilfrich, (unknown), Annette Staebler, (unknown), Beyhan Ataseven, Thomas Kirchner, Manfred Dietel, Michael Untch, Gϋnter von Minckwitz	19
7	The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use 2012 ·Annals of Oncology ·W. Eiermann, Mahdi Rezai, Sherko Kümmel, Thorsten Kühn, M Warm, Kay Friedrichs, Andreas Schneeweiß, Susanne Markmann, Holm Eggemann, J. Hilfrich, Christian Jackisch, Isabell Witzel, Holger Eidtmann, (unknown), (unknown), Jens‐Uwe Blohmer	116
8	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial 2012 ·The Lancet Oncology ·Michael Untch, Sibylle Loibl, Joachim Bischoff, Holger Eidtmann, Manfred Kaufmann, Jens‐Uwe Blohmer, J. Hilfrich, Dirk Strumberg, Peter A. Fasching, R. Kreienberg, Hans Tesch, Claus Hanusch, Bernd Gerber, Mahdi Rezai, Christian Jackisch, Jens Huober, Thorsten Kühn, Valentina Nekljudova, Gϋnter von Minckwitz	297
9	Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial 2010 ·Clinical Cancer Research ·Sabine Riethdorf, Volkmar Müller, Liling Zhang, Thomas Rau, Sibylle Loibl, Martina Komor, Marc Roller, Jens Huober, Tanja Fehm, Iris Schrader, J. Hilfrich, Frank Holms, Hans Tesch, Holger Eidtmann, Michael Untch, Gϋnter von Minckwitz, Klaus Pantel	398
10	Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial 2010 ·Annals of Oncology ·Jens‐Uwe Blohmer, Peter Schmid, J. Hilfrich, K Friese, Anke Kleine-Tebbe, Heinz Koelbl, H. Sommer, G Morack, Manfred Wischnewsky, W. Lichtenegger, Sherko Küemmel	18
11	Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study 2008 ·JNCI Journal of the National Cancer Institute ·Gϋnter von Minckwitz, Sherko Kümmel, (unknown), Claus Hanusch, Holger Eidtmann, J. Hilfrich, B. Gerber, Jens Huober, Serban Dan Costa, Christian Jackisch, Sibylle Loibl, K. Mehta, (unknown)	182
12	Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: Further results from a randomised controlled trial 2007 ·European Journal of Cancer ·Christine Müller, Angelika Caputo, Martin Schumacher, G. Raab, Martin Schütte, J. Hilfrich, Manfred Kaufmann, Gϋnter von Minckwitz	5
13	371 In vivo-chemosensitivity adapted primary chemotherapy in patients with primary breast cancer. First results of the Gepartrio-Pilot trial 2003 ·European Journal of Cancer Supplements ·Gϋnter von Minckwitz, (unknown), Jens‐Uwe Blohmer, B. Gerber, Alfredo Löhr, (unknown), (unknown), J. Hilfrich, (unknown), M. Kaufmann	4
14	Dose-Dense Biweekly Doxorubicin/Docetaxel Versus Sequential Neoadjuvant Chemotherapy with Doxorubicin/Cyclophosphamide/Docetaxel in Operable Breast Cancer: Second Interim Analysis 2002 ·Clinical Breast Cancer ·Christian Jackisch, Gϋnter von Minckwitz, Holger Eidtmann, Serban Dan Costa, Günther Raab, Jens‐Uwe Blohmer, Martin Schütte, Bernd Gerber, E. Merkle, G. Gademann, Dieter Lampe, J. Hilfrich, (unknown), Angelika Caputo, Manfred Kaufmann	36
15	Towards in-vitro prediction of an in-vivo cytostatic response of human tumor cells with a fast chemosensitivity assay 2001 ·Toxicology ·Robert P. Metzger, (unknown), (unknown), Svenja Zapf, J. Hilfrich	18
16	Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. 1993 ·Journal of Clinical Oncology ·M. Kaufmann, W. Jonat, Ulrich Abel, J. Hilfrich, H. Caffier, R. Kreienberg, (unknown), (unknown), (unknown), W. Kleine	43
17	Secretory differentiation of human fetal bronchial epithelial cells in culture 1990 ·Experimental Pathology ·Carsten Brockmeyer, M. Emura, Atsushi Ochiai, (unknown), U. Möhr, J. Hilfrich	11
18	Chemotherapie des fortgeschrittenen Ovarialkarzinoms 1985 ·Oncology Research and Treatment ·H. Kühnle, J. Hilfrich	3
19	Studies of the ovaries of hibernating and non-hibernating European hamsters (Cricetus cricetus). 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·J. Hilfrich, (unknown), (unknown)	1
20	Vergleichende experimentelle Untersuchungen zur karzinogenen Wirkung von 7,12-Dimethylbenz(a)anthracen (DMBA) am Ovargewebe der Ratte und Maus 1975 ·Archives of Gynecology and Obstetrics ·J. Hilfrich	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact